Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.

Authors

Joanna J. Chmielinska, George Washington University
Jay H. Kramer, George Washington University
I-Tong Mak, George Washington University
Christopher F. Spurney
William B. Weglicki, George Washington University

Document Type

Journal Article

Publication Date

12-18-2019

Journal

Molecular and Cellular Biochemistry

DOI

10.1007/s11010-019-03677-7

Comments

Epub ahead of print

APA Citation

Chmielinska, J. J., Kramer, J. H., Mak, I., Spurney, C. F., & Weglicki, W. B. (2019). Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.. Molecular and Cellular Biochemistry, (). http://dx.doi.org/10.1007/s11010-019-03677-7

Peer Reviewed

1